Drugs / Monovalent RSV Vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06583031 | Oct 2024 → Oct 2025 | respiratory syncytial virus infectious disease | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Monovalent RSV Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06583031 ↗ |
| Modality | Vaccine | “Monovalent RSV Vaccine” NCT06583031 ↗ |
| Route | Intramuscular | “Route of administration: IM injection” NCT06583031 ↗ |